Simplex Trading, LLC Viracta Therapeutics, Inc. Transaction History

Simplex Trading, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$0.5 - $1.17 $1,226 - $2,870	2,453 Added 50.23%	7,337 $3,000
Q1 2024 Apr 25, 2024	BUY	$0.48 - $1.13 $2,344 - $5,518	4,884 New	4,884 $4,000
Q3 2023 Nov 01, 2023	BUY	$1.03 - $1.58 $1,176 - $1,804	1,142 New	1,142 $1,000
Q4 2022 Feb 02, 2023	SELL	$1.26 - $4.38 $10,843 - $37,694	-8,606 Reduced 97.32%	237 $0
Q3 2022 Nov 04, 2022	BUY	$3.32 - $5.69 $4,339 - $7,436	1,307 Added 17.34%	8,843 $37,000
Q2 2022 Aug 03, 2022	BUY	$1.87 - $5.0 $9,505 - $25,415	5,083 Added 207.22%	7,536 $29,000
Q1 2022 May 02, 2022	BUY	$2.23 - $4.76 $4,413 - $9,420	1,979 Added 417.51%	2,453 $11,000
Q4 2021 Feb 23, 2022	BUY	$3.37 - $7.91 $1,597 - $3,749	474 New	474 $1,000

3.66M

1.8K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $1.13M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.